cytoreductive surgery for ovarian cancer
Conditions
Interventions
Contral Group: normal saline
dextrometomidine combined with ropivacaine group:dextrometomidine combined with ropivacaine
Sponsors
Department of Anesthesiology, the First Affiliated Hospital of USTC; Division of Life Sciences and Medicine, University of Science and Technology of China,
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. ASA physical fitness level I-III; 2. Body Mass Index:18.523.9 kg/m2; 3. Aged 18-80 years; 4. Patients undergoing cytoreductive surgery for ovarian cancer (including recurrent ovarian cancer and complex ovarian cancer).
Exclusion criteria
Exclusion criteria: 1. Patients with a previous history of abdominal surgery other than cytoreductive surgery for ovarian cancer; 2. Patients with coagulopathy and tendency of nose bleeding; 3. Patients with severe systemic diseases; 4. Patients with a history of opioid or alcohol abusea; 5. Patients with severe sequelae from neurological disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postoperative VAS pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| the first request time for PCIA bolus ; postoperative opioid administered ;dosageof postoperative rescue drugs;The occurrence of postoperative adverse reactions;postoperative recovery; | — |
Countries
China
Contacts
Public ContactZhang Wei
General Hospital of Anhui Provincial Hospital, The First Affiliated College of China University of Science and Technology
Outcome results
None listed